MTAP and prostate cancer: In summary, the IHC analysis of 13,189 prostate cancers revealed that MTAP deficiency is exceedingly rare, that high MTAP expression is a strong and statistically independent marker for poor prognosis in ERG negative cancers, and that ERG activation fully reverses these MTAP effects even linking high MTAP expression to favorable outcome.